Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults (≥ 18 and ≤ 45 years), toddlers (≥ 2 and ≤ 3 years), and infants (≥ 6 and ≤ 8 weeks)~* Participants will remain in the area during the study~* Females of childbearing potential must not be pregnant or breastfeeding, and willing to use adequate method of contraception during the trial.~Exclusion Criteria:~* Presence of fever or other acute illness~* concurrent participation in another clinical trial~* Presence of malnutrition or other systemic disorder.~* Infants with history of premature birth (\< 37 week gestational age)~* History of congenital abdominal disorders or surgery~* Suspected or known impairment of immune function~* Infants who have received rotavirus vaccine in the past~* Known sensitivity to any components of the vaccine~* History of anaphylactic reaction~* Major congenital or genetic defect~* Unwillingness to follow study schedule~* Receipt of immunoglobulin therapy or blood products in last 6 months~* History of chronic immunosuppressive medications (with the exception of inhaled or topical steroids)~* Any medical condition that, in the judgement of the investigator, would interfere with the protocol, or would interfere with participant's ability to adhere to the study protocol.~* Clinically significant screening laboratory value~* Human immunodeficiency virus (HIV) infection

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Adults: Placebo (Type: PLACEBO_COMPARATOR): Adults received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
- Adults: 30 µg P2-VP8 (Type: EXPERIMENTAL): Adults received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
- Adults: 90 µg P2-VP8 (Type: EXPERIMENTAL): Adults received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
- Toddlers: Placebo (Type: PLACEBO_COMPARATOR): Toddlers received one intramuscular injection of placebo on Day 0.
- Toddlers: 30 µg P2-VP8 (Type: EXPERIMENTAL): Toddlers received one intramuscular injection of 30 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
- Toddlers: 90 µg P2-VP8 (Type: EXPERIMENTAL): Toddlers received one intramuscular injection of 90 µg trivalent P2-VP8 subunit rotavirus vaccine on Day 0.
- Infants: Placebo (Type: PLACEBO_COMPARATOR): Infants received three intramuscular injections of placebo four weeks apart on Days 0, 28, and 56.
- Infants: 15 µg P2-VP8 (Type: EXPERIMENTAL): Infants received three intramuscular injections of 15 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
- Infants: 30 µg P2-VP8 (Type: EXPERIMENTAL): Infants received three intramuscular injections of 30 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.
- Infants: 90 µg P2-VP8 (Type: EXPERIMENTAL): Infants received three intramuscular injections of 90 µg trivalent P2-VP8 subunit rotavirus vaccine four weeks apart on Days 0, 28, and 56.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete